Skip to main content

Share story

Capital AI

NAVER D2SF joins $10M bridge for ImpriMed's AI precision medicine push

NAVER's Venture Capital Arm Invests in U.S. AI Precision Medicine Startup ImpriMed Image: Primary
NAVER's corporate venture arm D2SF participated in a $10 million Series A2 bridge for ImpriMed, a Silicon Valley AI precision medicine company, the investor said. LB Investment led the round, joined by Samsung Securities and Alois Ventures, with BonAngels and Han River Partners increasing commitments. ImpriMed combines ex vivo analysis of live patient-derived cancer cells with genomic and clinical data to recommend treatments. It targets blood cancers and bloodstream infections, aiming for FDA clearance and CLIA certification by the first quarter of 2027, and cites Mayo Clinic among commercial partners. The company says its models have accumulated more than 3.5 million data points.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from finance.biggo.com and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
AI Capital
AI Capital

Trajectory raises $45 million and opens model post-training platform

Trajectory has raised $45 million in Series A funding at a $300 million valuation and is making its model post-training platform publicly available, TechCrunch reported. Sequoia led the round, with participation from Nvidia, Bessemer Venture Partners and Bain Capital Ventures.

Robotics AI
Robotics AI

Tutor raises $75M Series B led by a16z

Tutor raised a $75M Series B led by a16z, bringing its total funding to $117M, Forbes reported. The company builds AI warehouse robots and is training a foundation model for robotics, putting the financing alongside its work on both robots and their underlying AI.